Applied DNA Executes New Two-Year Contract with the U.S. Defense Logistics Agency
Continues Support of On-Site SigNature® DNA Program at Land and Maritime Since December 2014
STONY BROOK N.Y., September 11, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, announced today the signing of a new contract to continue uninterrupted service of the Company’s DNA marking program at the Defense Logistics Agency’s (DLA) Land and Maritime’s Product Test Center (PTC) in Columbus, Ohio. The firm fixed price, indefinite delivery contract (IDC) was awarded on September 6th and spans a two-year period of performance. In addition, the contract allows for a one-year option period to be exercised at the discretion of DLA. The contract outlines the Company’s provision of supplies and services, including creation of unique DNA marks in various inks, QC authentication testing and training. These services and supplies directly support DLA’s counterfeit prevention initiatives, product verification and testing programs specific to FSC 5962 microcircuits in place at the Agency.
“We appreciate the DLA’s continuing support of our taggant technology platform in extending this contract for the marking of system-critical microcircuits,” stated Janice Meraglia, Vice President of Government and Military Programs at Applied DNA. “It is our honor to be part of DLA’s Warfighter First mission that is dedicated to supporting the men and women that protect our country.”
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-molecular based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Cheryl Schneider, Dian Griesel Int’l, 212-825-3210, cschneider@dgicomm.com
program contact: Janice Meraglia, Vice President, Government and Military Programs, 631-240-8821, janice.meraglia@adnas.com
web: www.adnas.com | twitter: @APDN